InxMed Co., Ltd | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

18,329 results for “InxMed Co., Ltd”

InxMed's Ifebemtinib Receives Breakthrough Therapy Designation for NSCLC with KRAS G12C Mutation

InxMed Reports Breakthrough Results for Ifebemtinib-Garsorasib Combination in KRAS G12C-Mutant Cancers at ASCO 2025

Ifebemtinib Plus Garsorasib Shows 82% ORR and 22-Month PFS in First-Line KRAS G12C-Mutant NSCLC

Eisai Advances LEQEMBI Subcutaneous and IV Maintenance Dosing Applications for Alzheimer's Disease

AIM Vaccine Submits 13-Valent Pneumonia Conjugate Vaccine for Approval After Positive Phase III Results

Rege Nephro Secures $150 Million in Series B Funding to Advance Kidney Disease Therapies

Lumosa Therapeutics' LT3001 Shows Promise in Phase II Acute Ischemic Stroke Trial

Dizal Submits NDA to FDA for Sunvozertinib in EGFR Exon20ins NSCLC

Newron Pharmaceuticals Expands Evenamide Reach in Asia with New Licensing Agreements

AIM Vaccine's Serum-Free Rabies Vaccine Achieves Phase III Goals, Paving Way for Market Launch

Page 1 of 782